Green Cross’s HCC Immunotherapy Set For Phase II
This article was originally published in PharmAsia News
Executive Summary
Hoping to expand its presence in the cancer immunotherapy space, South Korea's Green Cross is planning to begin a ground-breaking Phase II clinical program for a novel allogeneic natural killer cell therapy against hepatocellular carcinoma.